» Articles » PMID: 9116013

The Photoactivatable Inhibitor 7-azido-8-iodoketanserin Labels the N Terminus of the Vesicular Monoamine Transporter from Bovine Chromaffin Granules

Overview
Journal Biochemistry
Specialty Biochemistry
Date 1997 Mar 18
PMID 9116013
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In monoaminergic cells, the hormone or neurotransmitter is concentrated into secretory vesicles by a tetrabenazine- and reserpine-sensitive vesicular monoamine transporter (VMAT), catalyzing a H+/monoamine antiport. Ketanserin is another powerful inhibitor of VMAT that binds to the tetrabenazine binding site. A photoactivatable derivative, 7-azido-8-iodoketanserin (AZIK), labels covalently the transporter from bovine chromaffin granules, VMAT-2. Digestion with endoproteinases V8 or Lys-C, which cleave peptide bonds at acidic or lysine residues, respectively, revealed that the AZIK label is located in a 7 kDa segment of the VMAT-2 polypeptide. The photolabeled chromaffin granule transporter was purified by DEAE and WGA chromatography followed by selective aggregation and size-exclusion HPLC. After treatment by V8 or Lys-C, digestion products were separated by electrophoresis in SDS and sequenced. For both enzymes, the material comigrating with the labeled peptide produced a sequence matching the N terminus of VMAT-2. A K55E mutant of the bovine VMAT-2 cDNA was constructed and expressed in COS-7 cells. The mutant protein exhibited a full VMAT activity and could be labeled by AZIK. However, the formation of the 7 kDa labeled peptide upon Lys-C proteolysis was prevented in the mutant, with a redistribution of the label in higher-molecular mass digestion products. The localization of the label upstream of lysine 55 was confirmed by an immunological and enzymatic analysis. We conclude that the segment 2-55 of bovine VMAT-2, which encompasses the cytosolic N terminus and the first transmembrane segment in the current topological model of the transporter, contains residues involved in the binding of ketanserin and, possibly, tetrabenazine.

Citing Articles

The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Nickell J, Siripurapu K, Vartak A, Crooks P, Dwoskin L Adv Pharmacol. 2014; 69:71-106.

PMID: 24484975 PMC: 4084610. DOI: 10.1016/B978-0-12-420118-7.00002-0.


Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.

Ugolev Y, Segal T, Yaffe D, Gros Y, Schuldiner S J Biol Chem. 2013; 288(45):32160-32171.

PMID: 24062308 PMC: 3820856. DOI: 10.1074/jbc.M113.502971.


Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Wimalasena K Med Res Rev. 2010; 31(4):483-519.

PMID: 20135628 PMC: 3019297. DOI: 10.1002/med.20187.


The neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go(2).

Holtje M, von Jagow B, Pahner I, Lautenschlager M, Hortnagl H, Nurnberg B J Neurosci. 2000; 20(6):2131-41.

PMID: 10704487 PMC: 6772484.


Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function.

Varoqui H, Erickson J Mol Neurobiol. 1997; 15(2):165-91.

PMID: 9396009 DOI: 10.1007/BF02740633.